Engineered immune cells take on tough EBV cancers in early trial
NCT ID NCT07306156
First seen Jan 05, 2026 · Last updated May 02, 2026 · Updated 12 times
Summary
This study tests a new treatment called GP350 CAR-T cells for people with blood cancers linked to the Epstein-Barr virus that have not responded to standard therapy. About 24 participants will receive their own immune cells, modified in a lab to target the virus, after a short course of chemotherapy. The goal is to see if the treatment can shrink tumors and clear the virus from the blood, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOID NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.